Contrast-induced nephropathy;Néphropathie au produit de contraste

Revue Medicale Suisse

Volumn 9, Issue 389, 2013, Pages 1222-1228

  Humbert, A ^a   Kissling, S ^a   Teta, D ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; GADOLINIUM; INFUSION FLUID; IODINE; PLASMA SUBSTITUTE; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ARTICLE; CONTRAST INDUCED NEPHROPATHY; MORBIDITY; MORTALITY; PREVENTION; RISK ASSESSMENT;

ALGORITHMS; CONTRAST MEDIA; HUMANS; INCIDENCE; KIDNEY DISEASES; MODELS, BIOLOGICAL; PROGNOSIS; RISK FACTORS;

EID: 84878879244     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. *Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: Updated ESUR contrast media safety committee guidelines. Eur Radiol 2011;21:2527-41.
2. **Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2012; (Suppl. 1):S1-138.
3. **The ad-hoc working group of ERBP. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012;27:4263-72.
4. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;6:14-22. (Pubitemid 43181360)
5. Bucaloiu ID, Kirchner HL, Norfolk ER, et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81:477-85.
6. Claure-Del Granado R, Macedo E, Chertow GM, et al. Toward the optimal dose metric in continuous renal replacement therapy. Int J Artif Organs 2012;35:413-24.
7. Macedo E, Malhotra R, Claure-Del Granado R, et al. Defining urine output criterion for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2011;26:509-15.
8. Siew ED, Matheny ME, Ikizler TA, et al. Commonly used surrogatesfor baseline renal function affect the classification and prognosis ofacute kidney injury. Kidney Int 2010;77:536-42.
9. Nyman U, Bjork J, Aspelin P, et al. Contrast medium dose-to-GFR ratio: A measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. Acta Radiol 2008;49:658-67.
10. Heinrich MC, Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: Metaanalysis of randomized controlled trials. Radiology 2009;250:68-86.
11. Kane GC, Stanson AW, Kalnicka D, et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: Clinical outcomes. Nephrol Dial Transplant 2008;23:1233-40. (Pubitemid 351767477)
12. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-9.
13. Elmholdt TR, Jørgensen B, Ramsing M, et al. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010;3:285-7.
14. Bruce RJ, Djamali A, Shinki K, et al. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. Am J Roentgenol 2009;192:711-8.
15. *Lameire NH. Contrast-induced nephropathy - prevention and risk reduction. Nephrol Dial Transplant 2006;21:i11-i23. (Pubitemid 43978561)
16. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: A randomised study. Indian Heart J 1999;51:521-6. (Pubitemid 30139601)
17. Choyke PL, Cady J, DePollar SL, et al. Determination of serum creatinine prior to iodinated contrast media: Is it necessary in all patients? Tech Urol 1998;4:65-9. (Pubitemid 28237617)
18. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-9. (Pubitemid 39303939)
19. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75. (Pubitemid 27506242)
20. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? J Nephrol 2009;22:333-51.
21. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20. (Pubitemid 24348355)
22. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36. (Pubitemid 34127411)
23. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291:2328-34. (Pubitemid 38656299)
24. *Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: Sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009;151:631-8.
25. Cho R, Javed N, Traub D, et al. Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease. J Interv Cardiol 2010;23:460-6.
26. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4. (Pubitemid 30489215)
27. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008;3:281-7.
28. *The ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011;124:1250-9.
29. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111:692-8. (Pubitemid 34017520)
30. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006;119:155-62. (Pubitemid 43151482)
31. Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy. Circulation 2012;126:296-303.
32. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126:3008-16.
33. The REMEDIAL II Investigators. Renal insufficiency after contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation 2011;124:1260-9.